(Q45865401)

17 December 2017

title

Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes (English)

1 reference

17 December 2017

author name string

Hua Li

1

1 reference

17 December 2017

Samuel L Murphy

2

1 reference

17 December 2017

Wynetta Giles-Davis

3

1 reference

17 December 2017

Shyrie Edmonson

4

1 reference

17 December 2017

Zhiquan Xiang

5

1 reference

17 December 2017

Yan Li

6

1 reference

17 December 2017

Marcio O Lasaro

7

1 reference

17 December 2017

Katherine A High

8

1 reference

17 December 2017

Hildegund Cj Ertl

9

1 reference

17 December 2017

publication date

23 January 2007

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

15

1 reference

17 December 2017

issue

4

1 reference

17 December 2017

page(s)

792-800

1 reference

17 December 2017

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Identification of mouse AAV capsid-specific CD8+ T cell epitopes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

New AAV serotypes may broaden the therapeutic pipeline to human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Parvovirus-mediated gene transfer for the haemophilias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300090

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300090

1 reference

17 December 2017

PubMed ID

17245353

1 reference

17 December 2017